A Phase 1, Open-label, Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants
Latest Information Update: 08 Feb 2025
At a glance
- Drugs Afimetoran (Primary) ; Famotidine
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 27 May 2021 Status changed from active, no longer recruiting to completed.
- 21 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2020 New trial record